Compare Brookfield Infrastructure Partners LP (BIP) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Johnson & Johnson — how do they compare? Brookfield Infrastructure Partners LP trades at $39.48 (market cap $18.10B), while Johnson & Johnson trades at $260.74 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 34.6× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| BIP | JNJ | |
|---|---|---|
Market Cap | $18.10B | $626.09B |
Sector | Industrials | Health |
52-Week High | $42.62 | $267.24 |
52-Week Low | $29.81 | $172.78 |
Enterprise Value | $77.05B | $654.37B |
Dividend Yield | 4.62% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.
Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
